223 related articles for article (PubMed ID: 10219897)
21. [Human breast cancer embedded in paraffin, fixed in Bouin's fluid. Immunohistochemical analysis of estrogen and progesterone receptors].
Jacquemier J; Boudaoura T; Martin PM; Torrente M; Hassoun J
Ann Pathol; 1991; 11(4):224-30. PubMed ID: 1958256
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers.
Nadji M; Gomez-Fernandez C; Ganjei-Azar P; Morales AR
Am J Clin Pathol; 2005 Jan; 123(1):21-7. PubMed ID: 15762276
[TBL] [Abstract][Full Text] [Related]
23. Estrogen and progesterone receptor status of primary breast cancer: relationship with the pattern of first metastasis and survival.
Bhatavdekar JM; Patel DD; Karelia NH; Trivedi SN; Shah NG; Vora HH; Ghosh N; Balar DB
Neoplasma; 1992; 39(6):349-52. PubMed ID: 1491724
[TBL] [Abstract][Full Text] [Related]
24. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.
Balleine RL; Earl MJ; Greenberg ML; Clarke CL
Br J Cancer; 1999 Mar; 79(9-10):1564-71. PubMed ID: 10188907
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
26. Correlation of steroid receptors in synchronous tissues with survival in breast cancer patients.
Bhatavdekar JM; Patel DD; Karelia NH; Suthar TP; Shah NG; Vora HH; Ghosh N; Nadkarni SP; Balar DB
Neoplasma; 1993; 40(3):177-80. PubMed ID: 8350965
[TBL] [Abstract][Full Text] [Related]
27. Hormone receptor status and mitotic activity as risk factors for recurrence and death in female breast carcinoma.
Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
Anticancer Res; 1991; 11(5):1701-6. PubMed ID: 1768039
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
29. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significances of estrogen and progesterone receptors in primary operable breast cancer.
Kurebayashi J; Ishida T; Higashi Y; Suemasu K; Nomoto C; Yoshida K
Jpn J Clin Oncol; 1990 Sep; 20(3):271-80. PubMed ID: 2255103
[TBL] [Abstract][Full Text] [Related]
31. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
32. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
33. [Survival of patients with metastatic breast cancer according to pathological types of tumors].
Sánchez R C; Acevedo C F; Petric G M; Galindo A H; Domínguez C F; León R A; Razmilic V D; Ceballos C; Espinoza F; Navarro O ME; Oddó B D; Camus A M
Rev Med Chil; 2014 Apr; 142(4):428-35. PubMed ID: 25117032
[TBL] [Abstract][Full Text] [Related]
34. Results with accelerated partial breast irradiation in terms of estrogen receptor, progesterone receptor, and human growth factor receptor 2 status.
Wilder RB; Curcio LD; Khanijou RK; Eisner ME; Kakkis JL; Chittenden L; Agustin J; Lizarde J; Mesa AV; Macedo JC; Ravera J; Tokita KM
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):799-803. PubMed ID: 20869583
[TBL] [Abstract][Full Text] [Related]
35. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer.
Kuenen-Boumeester V; Van der Kwast TH; van Putten WL; Claassen C; van Ooijen B; Henzen-Logmans SC
Int J Cancer; 1992 Oct; 52(4):581-4. PubMed ID: 1399140
[TBL] [Abstract][Full Text] [Related]
37. Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods.
Seymour L; Meyer K; Esser J; MacPhail AP; Behr A; Bezwoda WR
Am J Clin Pathol; 1990 Oct; 94(4 Suppl 1):S35-40. PubMed ID: 1699410
[TBL] [Abstract][Full Text] [Related]
38. [Demonstration of the effect of estrogen and progesterone receptors on survival in breast cancer without cytostatic and hormonal treatment in a small set of patients].
Hochmann J
Klin Onkol; 2010; 23(1):25-33. PubMed ID: 20192071
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
40. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
